Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis
ESC Heart Fail
.
2022 Jun;9(3):2049-2050.
doi: 10.1002/ehf2.13812.
Epub 2022 Apr 5.
Authors
Lukasz Szarpak
1
2
,
Piotr Szwed
3
,
Aleksandra Gasecka
3
,
Zubaid Rafique
4
,
Michal Pruc
5
,
Krzysztof J Filipiak
1
,
Milosz J Jaguszewski
6
Affiliations
1
Maria Sklodowska-Curie Medical Academy, Warsaw, 03-411, Poland.
2
Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland.
3
1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
4
Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA.
5
Polish Society of Disaster Medicine, Warsaw, Poland.
6
First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.
PMID:
35384369
PMCID:
PMC9065811
DOI:
10.1002/ehf2.13812
No abstract available
Publication types
Letter
Meta-Analysis
MeSH terms
Cardiotonic Agents / therapeutic use
Dobutamine / therapeutic use
Heart Failure* / drug therapy
Humans
Milrinone* / therapeutic use
Substances
Cardiotonic Agents
Dobutamine
Milrinone